Jaen Juan C. 4
4 · Arcus Biosciences, Inc. · Filed Nov 19, 2025
Insider Transaction Report
Form 4
Jaen Juan C.
President
Transactions
- Sale
Common Stock
2025-11-18$19.75/sh−5,050$99,738→ 1,037,060 total(indirect: By Trust) - Sale
Common Stock
2025-11-17$20.23/sh−37,114$750,720→ 1,049,946 total(indirect: By Trust) - Sale
Common Stock
2025-11-17$20.71/sh−7,836$162,307→ 1,042,110 total(indirect: By Trust)
Holdings
- 367,220
Common Stock
Footnotes (4)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 8, 2025.
- [F2]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.65 to $20.645, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F3]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.65 to $20.82, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F4]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.48 to $20.17, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.